Table 5 Safety on varicella vaccination
From: Varicella infections in patients with end stage renal disease: a systematic review
| Reference | No of patient studied | Complications of vaccine | Main conclusions | Study quality |
|---|---|---|---|---|
| Crespo JF, et al. (2002) [16] | -17 seronegative patients completed vaccination protocol. |
-No secondary effect of vaccination detected. -None of the subsequently seroconverted patients who received kidney transplant presented with VZV disease (up to 18 months post renal transplant). | -Systematic vaccination prior to transplantation could prevent severe varicella. | Level 2 |
| Scanlon-Kohlroser CA,et al. (2002) [28] |
-A single case of 51yo woman at 6 months post-renal transplant developed a mild rash. -She had daily household contact with 15-month old twins vaccinated 40 days ago. | -Characteristic popular and vesicular rash over the face, trunk, extremities. No dissemination. Confirmed with positive VZV IgG 2 weeks later. |
-Transmission from those vaccinated to susceptible individuals are rare and typically occurs only if these patients develop a rash. - Contact cases develop a subclinical infection or mild illness; suggesting vaccine virus remains attenuated when vaccinated. | Level 3 |
| Geel AL, et al. (2006) [17] | -11 seronegative patients have been vaccinated with two doses VZV vaccine. | - No side effects, no fever, or skin lesions among all vaccinated patients. | -Vaccination should be performed in this group of patients in view of potentially lethal complications of primary varicella infection. | Level 2 |
| Kho MML, et al. (2016) [32] | -52 seronegative patients given two doses of VZV vaccine. |
-No severe vaccine-related adverse events were reported. - One had pain at injection site. -Two had zoster (3 months and 9 years post vaccination) -One patient developed mild varicella (18 days post vaccination). | Level 2 |
